StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms ...Middle East

BALDWIN PARK, Calif., Dec. 19, 2024 /PRNewswire/ -- StemCyte announced a significant breakthrough in its Phase IIa clinical trial of HPC, Cord Blood (HPC, CB) for treating Post-COVID Syndrome (Long COVID). This trial results demonstrated that cord blood significantly improved fatigue...

Hence then, the article about stemcyte announces successful phase iia clinical trial results for hpc cord blood in treating post covid syndrome 85 of patients experience complete relief from fatigue symptoms was published today ( Friday 20/12/2024 - 12:52 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms )

Also on site :

• ‘For All Mankind’ Star Joel Kinnaman and Creators Unpack [SPOILER]’s Death and Why It Was ‘the Hardest Ending to Craft’
• Natomas High School student shot near campus in Sacramento, police say
• ‘Good for Russia, good for China, bad for America’: How the Iran war is reshaping global economies and power